Serum soluble interleukin-2 receptor level as a prognostic indicator in gastric cancer
Author Information
Author(s): B Nakata, K Hirakawa, Y S Chung, Y Kato, Y Yamashita, A Inul, Y Arimoto, K Maeda, N Onoda, T Sawada, M Sowa
Primary Institution: Osaka City University Medical School
Hypothesis
The serum soluble interleukin-2 receptor (sIL-2R) level can serve as a prognostic indicator in gastric cancer patients.
Conclusion
Serum sIL-2R may predict the outcome of gastric cancer patients with stage III or IV disease.
Supporting Evidence
- Stage III and IV patients had significantly higher sIL-2R levels than lower stage patients and control subjects.
- The high sIL-2R group had a significantly worse prognosis than the low sIL-2R group.
- Multivariate analysis demonstrated that serum sIL-2R level is an independent prognostic indicator.
Takeaway
Doctors can check a substance in the blood called sIL-2R to see how likely it is that someone with advanced stomach cancer will do well.
Methodology
Serum sIL-2R levels were measured in 96 gastric cancer patients and 100 healthy controls using enzyme-linked immunosorbent assay.
Limitations
The study excluded patients with multiple cancers or autoimmune diseases, which may limit the generalizability of the findings.
Participant Demographics
Mean age of patients was 58.2 years, with a male-to-female ratio of 67:29.
Statistical Information
P-Value
0.0002
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website